MHRA (UK)
OTHER
Class 4 Medicines Defect Notification: Rayner Pharmaceuticals Limited, Dropodex 0.1% w/v Eye Drops, solution, EL(26)A/10
Published: 2/24/2026Detected: 3/22/2026
Summary preview
Notifies stakeholders of a quality defect in Dropodex 0.1% w/v Eye Drops due to the omission of phosphate concentration in product information, necessitating immediate communication to affected parties.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountophthalmology
labeling
#medicinal product defect
#labeling requirements
#phosphate concentration
#eye drops
#Rayner Pharmaceuticals
Official Source Document Source Verified
Access the original document directly from MHRA.
More from MHRA (UK)
- Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/4010/1/2026
- Field Safety Notices: 21 to 25 September 20269/29/2026
- MHRA Safety Roundup: September 20269/29/2026
- Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/399/23/2026
- Field Safety Notices: 14 to 18 September 20269/23/2026